Status:
ACTIVE_NOT_RECRUITING
Sentinel Lymph Node Detection in Gastric Cancer Using a Dual Tracer (Superparamagnetic Iron Oxide and Methylene Blue): A Prospective Study With Histological and OSNA Validation
Lead Sponsor:
Hospital del SAS de Jerez
Collaborating Sponsors:
Sysmex España
Conditions:
Gastric Cancer (GC)
Sentinel Lymph Node Biopsy (SLNB)
Eligibility:
All Genders
18+ years
Brief Summary
Gastric cancer (GC) remains an oncological challenge, where lymph node involvement is a key prognostic factor. Sentinel lymph node (SLN) mapping may improve staging and reduce surgical morbidity. This...
Detailed Description
Observational, prospective and analytical study, carried out in a second level university hospital with 500 inpatient beds. All patients with an indication for oncological gastric surgery who met the...
Eligibility Criteria
Inclusion
- Patients over 18 years of age with a diagnosis of gastric adenocarcinoma, undergoing surgery with curative intent by total or subtotal gastrectomy, accompanied by D1, D1+ or D2 lymphadenectomy, and with preoperative positivity for cytokeratin 19 (CK19) in the tumour sample.
Exclusion
- Patients with gastric cancer recurrence, those diagnosed with other active neoplasms, metastatic disease at diagnosis, as well as patients with Siewert type I and II gastrooesophageal junction carcinoma. Neoadjuvant treatment was not considered an exclusion criterion.
Key Trial Info
Start Date :
August 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT07147452
Start Date
August 1 2017
End Date
August 1 2025
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Univesrsity Hospital of Jerez Frontera
Jerez de la Frontera, CADIZ, Spain, 11403